News

Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
NBC Chicago3d
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Caremark negotiated an undisclosed lower net ... meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly.
NVO’s Mixed Q1 Results, Files for Oral GLP-1 Drug for Obesity
Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings ...
Zacks Investment Research on MSN14h
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...